featured
Daclatasvir Plus Sofosbuvir for Hepatitis C Virus Genotype 3
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Hepatology (Baltimore, Md.)
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study
Hepatology 2015 Apr 01;61(4)1127-1135, DR Nelson, JN Cooper, JP Lalezari, E Lawitz, PJ Pockros, N Gitlin, BF Freilich, ZH Younes, W Harlan, R Ghalib, G Oguchi, PJ Thuluvath, G Ortiz-Lasanta, M Rabinovitz, D Bernstein, M Bennett, T Hawkins, N Ravendhran, AM Sheikh, P Varunok, KV Kowdley, D Hennicken, F McPhee, K Rana, EA HughesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.